From Nasdaq: 2025-06-13 02:32:00

United Therapeutics (UTHR) shares rose 3.5% to $286.14, with high volume trading. The stock had previously dropped 7.7% in the past four weeks. This jump follows positive results from a pulmonary arterial hypertension study by Insmed, evaluating a prodrug formulation of UTHR’s treprostinil for once-daily dosing.

UTHR is expected to report earnings of $6.87 per share, a 17.4% increase YoY, with revenues of $796.42 million, up 11.4%. Positive earnings estimate revisions can lead to price appreciation, with UTHR holding a Zacks Rank #3 (Hold) in the Medical – Drugs industry. Keep an eye on this stock for further developments.

BioCryst Pharmaceuticals (BCRX) closed down 2% at $10.40, with a 7.7% return in the past month. The company is expected to report earnings of $0.02 per share, a 133.3% increase YoY. BCRX holds a Zacks Rank #2 (Buy) in the same industry, showing stability in EPS estimates over the past month.

Experts have identified 7 elite stocks, including UTHR and BCRX, with strong potential for early price pops. These handpicked stocks have historically outperformed the market by 2X, with an average gain of +23.5% per year. Investors are advised to give these stocks immediate attention for potential growth opportunities.



Read more at Nasdaq: United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?